Peng Ye1, Peiling Cai1, Jing Xie2, Yuanyuan Wei3. 1. Department of Anatomy and Histology, School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China. 2. Department of Pathology and Clinical Laboratory, Sichuan Provincial Fourth People's Hospital, Chengdu, Sichuan Province, People's Republic of China. 3. Department of Physiology, School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan Province, People's Republic of China.
Abstract
INTRODUCTION: Before anti-EGFR therapy is given to patients with colorectal cancer, it is required to determine KRAS mutation status in tumor. When tumor tissue is not available, cell-free DNA (liquid biopsy) is commonly used as an alternative. Due to the low abundance of tumor-derived DNA in cell-free DNA samples, methods with high sensitivity were preferred, including digital polymerase chain reaction, amplification refractory mutation system and next-generation sequencing. The aim of this systemic review and meta-analysis was to investigate the accuracy of those methods in detecting KRAS mutation in cell-free DNA sample from patients with colorectal cancer. METHODS: Literature search was performed in Pubmed, Embase, and Cochrane Library. After removing duplicates from the 170 publications found by literature search, eligible studies were identified using pre-defined criteria. Quality of the publications and relevant data were assessed and extracted thereafter. Meta-DiSc and STATA softwares were used to pool the accuracy parameters from the extracted data. RESULTS: A total of 33 eligible studies were identified for this systemic review and meta-analysis. After pooling, the overall sensitivity, specificity, and diagnostic odds ratio were 0.77 (95%CI: 0.74-0.79), 0.87 (95%CI: 0.85-0.89), and 23.96 (95%CI: 13.72-41.84), respectively. The overall positive and negative likelihood ratios were 5.55 (95%CI: 3.76-8.19) and 0.29 (95%CI: 0.21-0.38), respectively. Area under curve of the summarized ROC curve was 0.8992. CONCLUSION: Digital polymerase chain reaction, amplification refractory mutation system, and next-generation sequencing had overall high accuracy in detecting KRAS mutation in cell-free DNA sample. Large prospective randomized clinical trials are needed to further convince the accuracy and usefulness of KRAS mutation detection using cfDNA/liquid biopsy samples in clinical practice. TRIAL REGISTRATION: PROSPERO CRD42020176682; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=176682.
INTRODUCTION: Before anti-EGFR therapy is given to patients with colorectal cancer, it is required to determine KRAS mutation status in tumor. When tumor tissue is not available, cell-free DNA (liquid biopsy) is commonly used as an alternative. Due to the low abundance of tumor-derived DNA in cell-free DNA samples, methods with high sensitivity were preferred, including digital polymerase chain reaction, amplification refractory mutation system and next-generation sequencing. The aim of this systemic review and meta-analysis was to investigate the accuracy of those methods in detecting KRAS mutation in cell-free DNA sample from patients with colorectal cancer. METHODS: Literature search was performed in Pubmed, Embase, and Cochrane Library. After removing duplicates from the 170 publications found by literature search, eligible studies were identified using pre-defined criteria. Quality of the publications and relevant data were assessed and extracted thereafter. Meta-DiSc and STATA softwares were used to pool the accuracy parameters from the extracted data. RESULTS: A total of 33 eligible studies were identified for this systemic review and meta-analysis. After pooling, the overall sensitivity, specificity, and diagnostic odds ratio were 0.77 (95%CI: 0.74-0.79), 0.87 (95%CI: 0.85-0.89), and 23.96 (95%CI: 13.72-41.84), respectively. The overall positive and negative likelihood ratios were 5.55 (95%CI: 3.76-8.19) and 0.29 (95%CI: 0.21-0.38), respectively. Area under curve of the summarized ROC curve was 0.8992. CONCLUSION: Digital polymerase chain reaction, amplification refractory mutation system, and next-generation sequencing had overall high accuracy in detecting KRAS mutation in cell-free DNA sample. Large prospective randomized clinical trials are needed to further convince the accuracy and usefulness of KRAS mutation detection using cfDNA/liquid biopsy samples in clinical practice. TRIAL REGISTRATION: PROSPERO CRD42020176682; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=176682.
Authors: N Normanno; R Esposito Abate; M Lambiase; L Forgione; C Cardone; A Iannaccone; A Sacco; A M Rachiglio; E Martinelli; D Rizzi; S Pisconti; M Biglietto; R Bordonaro; T Troiani; T P Latiano; F Giuliani; S Leo; A Rinaldi; E Maiello; F Ciardiello Journal: Ann Oncol Date: 2018-01-01 Impact factor: 32.976
Authors: Alberto F Sobrero; Joan Maurel; Louis Fehrenbacher; Werner Scheithauer; Yousif A Abubakr; Manfred P Lutz; M Eugenia Vega-Villegas; Cathy Eng; Ernst U Steinhauer; Jana Prausova; Heinz-Josef Lenz; Christophe Borg; Gary Middleton; Hendrik Kröning; Gabriele Luppi; Oliver Kisker; Angela Zubel; Christiane Langer; Justin Kopit; Howard A Burris Journal: J Clin Oncol Date: 2008-04-07 Impact factor: 44.544
Authors: Evelyn Kidess-Sigal; Haiyan E Liu; Melanie M Triboulet; James Che; Vishnu C Ramani; Brendan C Visser; George A Poultsides; Teri A Longacre; Andre Marziali; Valentina Vysotskaia; Matthew Wiggin; Kyra Heirich; Violet Hanft; Ulrich Keilholz; Ingeborg Tinhofer; Jeffrey A Norton; Mark Lee; Elodie Sollier-Christen; Stefanie S Jeffrey Journal: Oncotarget Date: 2016-12-20
Authors: D C L Vessies; M J E Greuter; K L van Rooijen; T C Linders; M Lanfermeijer; K L Ramkisoensing; G A Meijer; M Koopman; V M H Coupé; G R Vink; R J A Fijneman; D van den Broek Journal: Sci Rep Date: 2020-05-15 Impact factor: 4.379